Merck’s Darmstadt Expansion: New €62 Million Facility to Elevate Quality Standards in Life Science

Merck’s Darmstadt Expansion: New €62 Million Facility to Elevate Quality Standards in Life Science

(IN BRIEF) Merck is investing €62 million in a new quality control facility at its Darmstadt headquarters as part of a larger €1.5 billion investment program. Scheduled for completion by mid-2025, the state-of-the-art facility will consolidate 135 employees into a collaborative space and adhere to stringent quality and sustainability standards.

(PRESS RELEASE) DARMSTADT, 12-Jun-2024 — /EuropaWire/ — In a strategic move aimed at bolstering its Life Science business, Merck, a leading science and technology company, has announced a €62 million investment in a new quality control building at its Darmstadt headquarters. This facility, scheduled for completion by mid-2025, will consolidate approximately 135 employees from various departments into a collaborative, state-of-the-art space spanning nearly 10,000 square meters.

The investment is part of Merck’s larger €1.5 billion investment program at the Darmstadt site by 2025, underscoring the company’s commitment to innovation and quality assurance in life science products. Robert Nass, Head of Quality & Regulatory Management for Merck’s Life Science business, emphasizes the critical role of quality control in ensuring the safety and efficacy of their products. The new facility reflects Merck’s dedication to delivering the highest quality and safest products to customers and patients worldwide.

Quality control is a crucial aspect of the life science industry, ensuring the purity and safety of products used in research, discovery, and manufacturing of medicines. Merck’s Life Science business boasts more than 25 specialized labs dedicated to quality control methods, facilitating rigorous testing to detect and eliminate any harmful substances.

Designed to meet the German Sustainable Building Council GOLD standard for sustainability, the facility will incorporate regenerative energy generation and low-CO2 construction techniques. Additionally, it will adhere to stringent safety requirements for genetic engineering and biology laboratories, as well as feature dust-free labs with specific hygiene protocols, all in compliance with Good Manufacturing Practice (GMP) standards.

Darmstadt serves as a key research and development center for Merck’s life science technologies, with approximately one-fifth of the Life Science business’s sales from new products expected to originate from this location over the next decade. The investment aims to expand Merck’s capacities and capabilities to meet the growing global demand for medicines while upholding the highest standards of quality and sustainability.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to to register online, change your selection or discontinue this service.

Media Contact:

Rachel Bloom Baglin
Phone: +49 (6151) 72-44461


Follow EuropaWire on Google News

Comments are closed.